Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa

BACKGROUND: The integrase strand transfer inhibitor (INSTI) dolutegravir is recommended in World Health Organization guidelines, but is associated with weight gain. We evaluated weight change in patients switching from efavirenz to dolutegravir in first-line antiretroviral therapy (ART) in Johannesb...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Alana T., Nattey, Cornelius, Kileel, Emma M., Rosen, Sydney, Maskew, Mhairi, Stokes, Andrew C., Fox, Matthew P., Venter, Willem D.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932660/
https://www.ncbi.nlm.nih.gov/pubmed/36816348
http://dx.doi.org/10.1016/j.eclinm.2023.101836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932660/
https://www.ncbi.nlm.nih.gov/pubmed/36816348
http://dx.doi.org/10.1016/j.eclinm.2023.101836

Ejemplares similares